FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286298688> ?p ?o ?g. }

• W4286298688 endingPage "e16156" @default.
• W4286298688 startingPage "e16156" @default.
• W4286298688 abstract "e16156 Background: Hyperprogressive disease (HPD) is characterized by an acceleration of tumor growth during systemic therapy, which usually refers to immunotherapy. The incidence of HPD in patients with hepatocellular carcinoma (HCC) is reported to be 12.7%. Amplification of the chromosome 11q13 locus, including cyclin D1 (CCND1), FGF3, FGF4 and FGF19, is frequent in many cancers and correlates with inferior outcomes with immunotherapy. However, little is known about the association between chromosome 11q13 amplification and HPD of HCC. Methods: 58 HCC patients who underwent the next-generation sequencing (NGS) in our institution from September 2017 to April 2018 were enrolled in this study. Among them, 30 patients had unresectable advanced or recurrent HCC and received anti-tumoral therapy, including 18 cases (Group 1) receiving programmed cell death-1 (PD-1) monoclonal antibody immunotherapy (with or without tyrosine kinase inhibitors, TKIs) and 12 cases (Group 2) receiving local regional therapy (with or without TKIs). Based on radiological surveillance, HPD was defined as: 1. Tumor growth kinetics (TGK) or tumor growth rate (TGR) > 2; 2. Time to treatment failure < 2 months. Results: In our dataset, chromosome 11q13 amplification (11q13 Amp) was seen in 11 patients (19.0%). 11q13 Amp was associated with worse clinical baseline, with a significant concentration in patients with BCLC C stage, tumor numbers of ≥ 3 and ECOG 1 score. Group 1 had an objective response rate (ORR) of 50.0% and Group 2 had an ORR of 54.5%. There was no significant difference in progression-free survival (PFS) between these two groups. 3 patients showed HPD in Group 1, all of whom carried 11q13 Amp. Compared to non-11q13 Amp patients, patients with 11q13 Amp had worse PFS (log-rank P= 0.001) in Group 1. While there was no significant difference of PFS between 11q13 Amp and non-11q13 Amp patients in Group 2. We further investigated the efficacy of different treatment strategies based on 11q13 Amp status. These 11q13 Amp patients in Group 1 showed worse PFS, compared to Group 2 (log-rank P= 0.025). However, patients with non-11q13 Amp showed similar outcomes between these two groups (log-rank P= 0.70). Conclusions: Our findings suggested that 11q13 Amp was associated with HPD of HCC. PD-1 monoclonal antibody showed poor efficacy in patients with 11q13 Amp, therefore targeted treatment strategies might be more suitable for such patients. Meanwhile, the role of 11q13 Amp as putative predictive biomarkers of HPD needs further validation in larger cohorts." @default.
• W4286298688 created "2022-07-21" @default.
• W4286298688 creator A5005328001 @default.
• W4286298688 creator A5023755657 @default.
• W4286298688 creator A5035500803 @default.
• W4286298688 creator A5041603535 @default.
• W4286298688 creator A5062468723 @default.
• W4286298688 creator A5076415782 @default.
• W4286298688 creator A5078275783 @default.
• W4286298688 date "2022-06-01" @default.
• W4286298688 modified "2023-10-16" @default.
• W4286298688 title "The association of chromosome 11q13 amplification with the hyperprogressive disease in unresectable hepatocellular carcinoma patients underwent the immunotherapy." @default.
• W4286298688 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e16156" @default.
• W4286298688 hasPublicationYear "2022" @default.
• W4286298688 type Work @default.
• W4286298688 citedByCount "1" @default.
• W4286298688 countsByYear W42862986882023 @default.
• W4286298688 crossrefType "journal-article" @default.
• W4286298688 hasAuthorship W4286298688A5005328001 @default.
• W4286298688 hasAuthorship W4286298688A5023755657 @default.
• W4286298688 hasAuthorship W4286298688A5035500803 @default.
• W4286298688 hasAuthorship W4286298688A5041603535 @default.
• W4286298688 hasAuthorship W4286298688A5062468723 @default.
• W4286298688 hasAuthorship W4286298688A5076415782 @default.
• W4286298688 hasAuthorship W4286298688A5078275783 @default.
• W4286298688 hasConcept C121608353 @default.
• W4286298688 hasConcept C126322002 @default.
• W4286298688 hasConcept C143998085 @default.
• W4286298688 hasConcept C2777701055 @default.
• W4286298688 hasConcept C2778019345 @default.
• W4286298688 hasConcept C71924100 @default.
• W4286298688 hasConcept C90924648 @default.
• W4286298688 hasConceptScore W4286298688C121608353 @default.
• W4286298688 hasConceptScore W4286298688C126322002 @default.
• W4286298688 hasConceptScore W4286298688C143998085 @default.
• W4286298688 hasConceptScore W4286298688C2777701055 @default.
• W4286298688 hasConceptScore W4286298688C2778019345 @default.
• W4286298688 hasConceptScore W4286298688C71924100 @default.
• W4286298688 hasConceptScore W4286298688C90924648 @default.
• W4286298688 hasIssue "16_suppl" @default.
• W4286298688 hasLocation W42862986881 @default.
• W4286298688 hasOpenAccess W4286298688 @default.
• W4286298688 hasPrimaryLocation W42862986881 @default.
• W4286298688 hasRelatedWork W1570838273 @default.
• W4286298688 hasRelatedWork W2337719538 @default.
• W4286298688 hasRelatedWork W2385390897 @default.
• W4286298688 hasRelatedWork W2404951810 @default.
• W4286298688 hasRelatedWork W2410885201 @default.
• W4286298688 hasRelatedWork W2417822880 @default.
• W4286298688 hasRelatedWork W2418745692 @default.
• W4286298688 hasRelatedWork W2809701302 @default.
• W4286298688 hasRelatedWork W3172842848 @default.
• W4286298688 hasRelatedWork W628600844 @default.
• W4286298688 hasVolume "40" @default.
• W4286298688 isParatext "false" @default.
• W4286298688 isRetracted "false" @default.
• W4286298688 workType "article" @default.